10. December 2018
Transglutaminase-Newsletter | December 2018
An exciting year is almost over. Looking back, it was another inspiring and stimulating year for the transglutaminase
community. All of us will keep the precious moments from the Gordon Research Conference in June in the Swiss Alps in mind.
Drug development programs targeting transglutaminases are moving forward - either via antibodies or small molecules.
Our TG2-blocker ZED1227 entered phase 2a proof-of-concept study in mid 2018.
Zedira is going to continue supporting your R&D efforts, either in academia or in industry with our specialty reagents.
Please find below an extract of our products. You can find more of them and additional information at zedira.com or just contact us (contact@zedira.com).
Sincerely yours,
On behalf of the entire Zedira team
Martin Hils and Ralf Pasternack
Microbial Transglutaminase, MTG
Tissue Transglutaminase, TG2
Coagulation Factor XIII, FXIII
Neuronal Transglutaminase, TG6
Our product highlights, your reliable transglutaminase tools!
Transglutaminase-Newsletter | December 2018 | Get your free Zedi-Coffee-CupUse Promo Code Zedi2019 on your next order until January 15th, 2019 |
An exciting year is almost over. Looking back, it was another inspiring and stimulating year for the transglutaminase
community. All of us will keep the precious moments from the Gordon Research Conference in June in the Swiss Alps in mind.
Drug development programs targeting transglutaminases are moving forward - either via antibodies or small molecules.
Our TG2-blocker ZED1227 entered phase 2a proof-of-concept study in mid 2018.
Zedira is going to continue supporting your R&D efforts, either in academia or in industry with our specialty reagents.
Please find below an extract of our products. You can find more of them and additional information at zedira.com or just contact us (contact@zedira.com).
Sincerely yours,
On behalf of the entire Zedira team
Martin Hils and Ralf Pasternack
Microbial Transglutaminase, MTG
| Art. No. | Name | Unit | Price |
| T001 | Microbial (bacterial) transglutaminase (MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis) | 25 U 250 U 10x 25 U 500 U 20x 25 U | 270 € 2140 € 2140 € 3750 € 3750 € |
| Z009 Application: | ZediXclusive Microbial Transglutaminase Assay Kit Determination of microbial transglutaminase activity | 1 Kit | 310 € |
| A145 Immunogen: | Polyclonal antibody to microbial transglutaminase Microbial transglutaminase (T001), raised in mouse | 200 µg | 365 € |
| C102 Application: | MTG-Blocker Inhibition of microbial transglutaminase, IC50 ~ 125 μM | 10 mg 25 mg | 210 € 385 € |
Tissue Transglutaminase, TG2
| Art. No. | Name | Unit | Price |
| T022 | Human tissue transglutaminase (hTG2, recombinantly produced in insect cells) | 250 µg 1 mg | 370 € 1100 € |
| M003 Application: | Tissue Transglutaminase Pico-Assay Kit Determination of tissue transglutaminase activity | 1 Kit | 395 € |
| A028 Format: | FITC-labeled polyclonal antibody to human TG2 A014 purified via affinity chromatography on protein A, followed by FITC-labeling | 200 µg | 395 € |
| Z006 Synonym: Application: | Z-DON-Val-Pro-Leu-OMe, „Z-DON“ Z-DON Irreversible inhibitor of tissue transglutaminase | 10 mg | 385 € |
Coagulation Factor XIII, FXIII
| Art. No. | Name | Unit | Price |
| T027 | Human blood coagulation Factor XIII-A2 (hFXIII, A subunit, recombinantly produced in insect cells) | 200 µg | 370 € |
| T070 | Human Factor XIIIa, Thrombin activated (hFXIIIa, recombinantly produced in insect cells) | 200 µg | 520 € |
| F001 Application: | FXIII-Assay Kit Ready to use, contains FXIII-Assay Substance (A101) and thrombin Fluorescent measurement of transglutaminase activity, optimized for FXIII | 1 Kit | 575 € |
| A108 Synonym: Application: | Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH ZED1301 Site specific irreversible inhibitor of plasma transglutaminase | 5 mg | 480 € |
Neuronal Transglutaminase, TG6
| Art. No. | Name | Unit | Price |
| T021 | Human neuronal transglutaminase (TG6, recombinantly produced in insect cells) | 250 µg | 475 € |
| E103 Antigen: | ZediXclusive TG6-ab ELISA (IgA) recombinant TG6, insect cells | 1 kit/ 96 wells | 520 € |
| E104 Antigen: | ZediXclusive TG6-ab ELISA (IgG) recombinant TG6, insect cells | 1 kit/ 96 wells | 520 € |
| A139 Specificity: | Monoclonal antibody to transglutaminase 6 (Catalytic Domain) Mouse monoclonal antibody reacts with the Catalytic Domain of human transglutaminase 6 | 200 µg | 365 € |
Successful ISO9001:2015 recertification 
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation